Definitive Contract 75A50126C00006
- Not listed
- This is a $24,631,080.00 definitive cost-reimbursement contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Sapphiros LLC, a for-profit foreign-owned organization. The contract is for the advanced research and development of a low-cost, connected, digital lateral flow platform to detect influenza A, influenza B, and SARS-CoV-2 for use in over-the-counter (OTC) settings. This contract was...
- The Office of the Assistant Secretary for Preparedness and Response (civilian agency within the Department of Health and Human Services) awarded a definitive contract to Wake Forest University Health Sciences for development of human organ tissue equivalent models of fibrosing chemical exposure to bridge preclinical and clinical translation of medical countermeasures, with a ceiling value of $48.6 million and an ultimate completion date of January 31, 2033. The award, issued on September 21,...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded Spectral MD, Inc. a $127.8 million definitive contract on September 30, 2023, for the development of a burn wound imaging technology device. The contract, structured as cost-plus-fixed-fee and extending through September 30, 2030, will be performed in Dallas, Texas. This award supports the Biomedical Advanced Research and Development Authority's objective to develop...
- This $100,000,000.00 definitive, firm fixed-price contract was awarded by the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services. The contract is for the design and administration of incentive prize competitions to accelerate the development and commercialization of new medical countermeasure technologies, with an initial focus on...
- The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $21.98 million cost-plus-fixed-fee contract to Biofire Defense LLC on September 29, 2023, with an ultimate completion date of July 31, 2029. The contract supports the advancement of the BioFire Emerging Flu Panel, a nucleic acid detection panel designed for use on the BioFire FilmArray Torch and BioFire Spotfire platforms. This award originated from a Biomedical Advanced Research and Development Authority...
- This is a $15,958,895.53 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Biofire Defense LLC, a for-profit limited liability company based in Salt Lake City, Utah. The contract is to advance the development of the Biofire Emerging COV Panel, a nucleic acid amplification test panel for use on the Biofire FilmArray 2.0 and FilmArray Torch molecular diagnostic platforms. This contract aligns with ASPR's mission to support the...
- The Department of Health and Human Services' Biomedical Advanced Research & Development Authority (BARDA) awarded a $25.5 million firm fixed-price definitive contract to Avita Medical Americas, LLC for the procurement and deployment of FDA-approved autograft sparing devices designed to reduce donor skin requirements for treating full-thickness thermal burn wounds. The contract, which commenced April 6, 2026 with an ultimate completion date of April 5, 2036, establishes a vendor-managed...
- This is a $249,923 firm fixed-price purchase order awarded by the Air Force Research Laboratory to Bloodstone Division LLC, a service-disabled veteran-owned small business based in Tampa, Florida. The contract is for the development of COVID-19 related medical products, including thermal insulation, vibration mitigation, and pressure injury reduction solutions for casualties. This contract is a Small Business Innovation Research (SBIR) Phase II award, indicating it is a follow-on to prior...
- This $34,714,763.00 cost-plus-fixed-fee contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Detect Inc. to advance the development of a second-generation, multi-analyte molecular SARS-CoV-2 and influenza A/B test that has a reduced time to result and increased sensitivity for use at home or in a point-of-care setting. The contract is not set aside. The award references a Broad Agency Announcement (BAA) issued by the Biomedical Advanced Research...
- This is a $9,183,030.00 firm fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Lumos Diagnostics, Inc., a self-certified small disadvantaged business, to execute a clinical method comparison study and regulatory submission required to obtain a Clinical Laboratory Improvement Amendments (CLIA) waiver from the Food and Drug Administration (FDA) for the FebriDx product. The contract was awarded on September 25, 2024 and has a period of...
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a $69.8 million definitive contract to Flosonics Medical LLC for advancement of FLOPatch FP120 with FLOPredict Alert, a burn and blast medical countermeasure, on June 15, 2026. The contract is structured as cost-sharing and incorporates Executive Order 14398. Work is performed in Mountain View, California. The contract extends through December 31, 2031. The award originated from the Biomedical Advanced Research and Development Authority (BARDA) solicitation posted September 26, 2023, which seeks advanced research and development proposals for medical countermeasures against CBRN threats, pandemic influenza, and emerging infectious diseases across twelve areas of interest. The solicitation operates through a three-stage process with evaluation based on program relevance, scientific and technical merit, offeror capabilities, cost realism, and past performance. All work must be performed in the United States, with preference for U.S.-based manufacturing and technologies adaptable to emerging threats. Development plans must cover regulatory pathways, manufacturing, clinical strategies, and commercialization, with compliance required for Good Manufacturing Practice standards, export control regulations, and intellectual property disclosure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0m | 6/4/26 |